Real-world survival ‘inferior’ to trials for ERBB2-positive metastatic cancer
Canadian breast cancer data differs from results seen in the CLEOPATRA and EMILIA trials, researchers report
Patient survival in the real-world is inferior to that seen in clinical trials of pertuzumab and trastuzumab emtansine for ERBB2-positive metastatic breast cancer, a study shows.
The cause is likely due to differences in patient characteristics and previous therapy, the Canadian researchers say.